PART I Item 1. Bu siness. We are a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. Our discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by our proprietary library of domains d...
Q2 FY2026 — expected 2026-09-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-05 | 2025-12-31 | 0001339970-26-000008 | EDGAR | 79K words |
| 2025-03-13 | 2024-12-31 | 0000950170-25-038888 | EDGAR | — |
| 2024-03-14 | 2023-12-31 | 0000950170-24-031584 | EDGAR | — |
| 2023-03-14 | 2022-12-31 | 0000950170-23-007873 | EDGAR | — |
| 2022-03-15 | 2021-12-31 | 0001564590-22-010441 | EDGAR | — |
| 2021-03-24 | 2020-12-31 | 0001564590-21-014940 | EDGAR | — |
| 2020-03-26 | 2019-12-31 | 0001564590-20-013208 | EDGAR | — |
| 2019-03-26 | 2018-12-31 | 0001564590-19-009381 | EDGAR | — |
| 2018-03-20 | 2017-12-31 | 0001564590-18-006333 | EDGAR | — |
| 2017-03-16 | 2016-12-31 | 0001564590-17-004631 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001193125-25-269587 | EDGAR | 53K words |
| 2025-08-07 | 2025-06-30 | 0001339970-25-000009 | EDGAR | — |
| 2025-05-07 | 2025-03-31 | 0000950170-25-065640 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123305 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0000950170-24-096185 | EDGAR | — |
| 2024-05-02 | 2024-03-31 | 0000950170-24-052092 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062058 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0000950170-23-040598 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0000950170-23-019686 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0000950170-22-024724 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0000950170-22-017401 | EDGAR | — |
| 2022-05-10 | 2022-03-31 | 0001564590-22-019293 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-05 | 0001339970-26-000006 | EDGAR | 3K words |
| 2025-12-05 | 0001193125-25-309619 | EDGAR | — |
| 2025-11-06 | 0001193125-25-269486 | EDGAR | — |
| 2025-09-15 | 0001193125-25-202865 | EDGAR | — |
| 2025-08-07 | 0001339970-25-000007 | EDGAR | — |
| 2025-05-07 | 0000950170-25-065611 | EDGAR | — |
| 2025-05-06 | 0000950170-25-064413 | EDGAR | — |
| 2025-03-13 | 0000950170-25-038703 | EDGAR | — |
| 2024-12-23 | 0000950170-24-139633 | EDGAR | — |
| 2024-12-12 | 0000950170-24-135766 | EDGAR | — |
221 total filings indexed. 189 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001339970 |
| Ticker | ATYR |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.atyrpharma.com |
| Listed | 2015-05-07 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report